rss
BMJ Case Reports 2012; doi:10.1136/bcr.02.2012.5814
  • Reminder of important clinical lesson

Successful use of allopurinol in a patient on dialysis

  1. Timothy J Furlong4
  1. 1Department of Clinical Pharmacology & Toxicology, St Vincent's Hospital, Sydney, New South Wales, Australia
  2. 2St Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia
  3. 3Department of Nephrology, St Vincent's Clinic, Sydney, New South Wales, Australia
  4. 4Department of Nephrology, St Vincent's Hospital, Sydney, New South Wales, Australia
  1. Correspondence to Professor Richard Osborne Day, r.day{at}unsw.edu.au

Summary

We report the case of a man with chronic tophaceous gout who had end-stage renal failure secondary to the Alport syndrome. Following a failed kidney transplant, where urate deposition was a suspected contributor, the patient responded positively to consistent allopurinol therapy and regular haemodialysis sessions. Extensive and destructive tophi receded in size remarkably and the almost constant incidence of acute attacks of gout subsided. The patient has recently received a new kidney transplant and his plasma concentrations of urate are controlled well with allopurinol and he no longer experiences acute attacks of gout. While efficacious, adherence is critical for achieving the therapeutic effects of allopurinol even in end-stage renal disease.

Footnotes

  • Competing interests None.

  • Patient consent Obtained.

Register for free content

The full text of all Editor's Choice articles and summaries of every article are free without registration

The full text of Images in ... articles are free to registered users

Only fellows can access the full text of case reports (apart from Editor's Choice) - become a fellow today, or encourage your institution to, so that together we can grow and develop this resource

Don't forget to sign up for content alerts so you keep up to date with all the case reports as they are published, and let us know what you think by commenting on the Editor's blog

Navigate This Article